PTX-100 shows encouraging efficacy signals and safety in area of high unmet clinical need
Clinical stage oncology company, Prescient Therapeutics, has a diverse stable of emerging and later stage...
Clinical stage oncology company, Prescient Therapeutics, has a diverse stable of emerging and later stage...
Prescient Therapeutics Shareholder Briefing In this session, Prescient Therapeutics CEO and MD Steven Yatomi-Clarke discussed:...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
Prescient Therapeutics CellPryme-A Briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of...
Prescient Therapeutics Investor Briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Kalkine Media...
Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke recently presented at the AusBiotech Investment Conference 2021....

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.